AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18025881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Metabolic Syndrome (MS) defined by IDF criteria
Number of subjects: 881
Study 18025881 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident Metabolic Syndrome (MS) defined by ATP-III criteria
Number of subjects: 881
Study 18025881 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident Metabolic Syndrome (MS) defined by IDF criteria
Number of subjects: 881
Study 15951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide 20 mg
Number of subjects: 0
Study 15951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide 60 mg
Number of subjects: 0
Study 15951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release lanreotide 90 mg
Number of subjects: 0
Study 15951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release lanreotide 120 mg
Number of subjects: 0
Study 12131941 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 86
Study 12131941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 86
Study 12131941 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 86
Study 12131941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 10325895 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily plus the run in dose of fluticasone propionate
Number of subjects: 274
Study 10325895 — intervention group
Group type: COMPARATOR
Intervention: Doubling the dose of fluticasone propionate (200 or 500 micrograms twice daily)
Number of subjects: 274
Study 7562165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 30
Study 7562165 — intervention group
Group type: COMPARATOR
Intervention: Inactive jelly
Number of subjects: 30
Study 1778684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/behavioral intervention plus cardiac counseling (E2)
Number of subjects: 0
Study 1778684 — intervention group
Group type: COMPARATOR
Intervention: Cardiac counseling only (C2)
Number of subjects: 0
Study 6192562 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon arc photocoagulation
Number of subjects: 0
Study 6192562 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study 30819358 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel pre-treatment
Number of subjects: 4001
Study 29746146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastball
Number of subjects: 20
Study 29746146 — intervention group
Group type: EXPERIMENTAL
Intervention: Changeup
Number of subjects: 20
Study 29746146 — intervention group
Group type: EXPERIMENTAL
Intervention: Curveball
Number of subjects: 20
Study 26959056 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day for six days)
Number of subjects: 30
Study 26959056 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30
Study 26959056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 30
Study 24550580 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg/day)
Number of subjects: 0
Study 24550580 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day) plus bromocriptine (0.8 mg/day)
Number of subjects: 0
Study 24550580 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day) plus bromocriptine (1.6 mg/day)
Number of subjects: 0
Study 22106246 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume fluid therapy (10 mL/kg/h)
Number of subjects: 107
Study 22106246 — intervention group
Group type: COMPARATOR
Intervention: Low-volume fluid therapy (4 mL/kg/h)
Number of subjects: 107
Study 20074867 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 2112
Study 20074867 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 2112
Study 20074867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 2112
Study 20074867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 2112
Study 17704795 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-type exercise, progressive relaxation and psychoeducation programme
Number of subjects: 19
Study 17704795 — intervention group
Group type: COMPARATOR
Intervention: Conventional care group (CC)
Number of subjects: 19
Study 15797676 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 18
Study 15797676 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 18
Study 12499786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200mg IV q 12 hours for 3 days
Number of subjects: 40
Study 12499786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 12499786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 40
Study 10338322 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depletion filter
Number of subjects: 40
Study 10338322 — intervention group
Group type: COMPARATOR
Intervention: Control filter
Number of subjects: 40
Study 7796076 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Synacthen Test (SST)
Number of subjects: 22
Study 7796076 — intervention group
Group type: COMPARATOR
Intervention: Insulin Tolerance Test (ITT)
Number of subjects: 22
Study 7796076 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ITT and SST
Number of subjects: 22
Study 7796076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response correlation
Number of subjects: 22
Study 2326330 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable reinforcement schedule (fixed-interval 90-sec)
Number of subjects: 52
Study 2326330 — intervention group
Group type: COMPARATOR
Intervention: Nonpredictable reinforcement schedule (random-interval 90-sec)
Number of subjects: 52
Study 2326330 — intervention group
Group type: COMPARATOR
Intervention: Random reinforcement schedule (nonpredictable)
Number of subjects: 52
Study 6104788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 236
Study 6104788 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 236
Study 31296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD and diabetes
Number of subjects: 0
Study 31296300 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 0
Study 31296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1% increase in HbA1c in patients with diabetes
Number of subjects: 0
Study 31296300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 0
Study 31296300 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment TIMI major bleeding in patients with diabetes
Number of subjects: 0
Study 27087507 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg
Number of subjects: 324
Study 27087507 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 324
Study 26445092 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention to reduce formula-milk intake, promote responsive feeding and healthy weaning, delivered over 6 months through three face-to-face contacts, two telephone contacts, and written materials.
Number of subjects: 650
Study 26445092 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same number of contacts discussing general feeding issues.
Number of subjects: 650
Study 23351597 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (capsule) of levodropropizine 60 mg
Number of subjects: 36
Study 23351597 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (syrup) of levodropropizine 60 mg
Number of subjects: 36
Study 23351597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (capsule and syrup)
Number of subjects: 36
Study 20680012 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation-focused maintenance program
Number of subjects: 338
Study 20680012 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based maintenance approach
Number of subjects: 338
Study 20680012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study 19750832 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact technique (48 eyes)
Number of subjects: 111
Study 19750832 — intervention group
Group type: COMPARATOR
Intervention: Immersion technique (63 eyes)
Number of subjects: 111
Study 19750832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 111
Study 16924006 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) ultrasonography
Number of subjects: 112
Study 16924006 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 112
Study 11057790 — intervention group
Group type: COMPARATOR
Intervention: Survanta (100 mg/kg) - 0 doses
Number of subjects: 27
Study 11057790 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 1 dose
Number of subjects: 27
Study 11057790 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 2 doses
Number of subjects: 27
Study 11057790 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta (100 mg/kg) - 3 doses
Number of subjects: 27
Study 11057790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal corticosteroid treatment
Number of subjects: 27
Study 11057790 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of patent ductus arteriosus
Number of subjects: 27
Study 8649872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (I)
Number of subjects: 70
Study 8649872 — intervention group
Group type: COMPARATOR
Intervention: Chronic sinusitis patients without cystic fibrosis (C)
Number of subjects: 70
Study 2000045 — intervention group
Group type: EXPERIMENTAL
Intervention: methionyl recombinant human growth hormone (met‐hGH) 0.06 IU/kg
Number of subjects: 12
Study 2000045 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study 6393665 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 6393665 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized therapy
Number of subjects: 0
Study 6393665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nation-wide study
Number of subjects: 0
Study 31490424 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg CAF + 100 mg CA
Number of subjects: 10
Study 31490424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted sleeping position
Number of subjects: 408
Study 31248711 — intervention group
Group type: COMPARATOR
Intervention: Restricted sleeping position
Number of subjects: 408
Study 31248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 408
Study 29310688 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day EPA/DHA
Number of subjects: 0
Study 29310688 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/day EPA/DHA
Number of subjects: 0
Study 29310688 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 0
Study 29310688 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA therapy
Number of subjects: 0
Study 27305950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made lifestyle intervention (diet and exercise) lasting 2.5 years
Number of subjects: 0
Study 27305950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made lifestyle intervention (diet and exercise)
Number of subjects: 0
Study 25440805 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine early invasive strategy
Number of subjects: 2974
Study 25440805 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 2974
Study 22214903 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (GABARα1-selective agonist)
Number of subjects: 0
Study 20588058 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 68
Study 20588058 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan 12 mg/day
Number of subjects: 68
Study 20588058 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan 40 mg/day
Number of subjects: 68
Study 20588058 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 68
Study 16887213 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation
Number of subjects: 3059
Study 16887213 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a diagnosis of hypertension
Number of subjects: 3059
Study 16240208 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 261
Study 16240208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 11867107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta radiation with a phosphorus-32 source (n=166)
Number of subjects: 332
Study 11867107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=166)
Number of subjects: 332
Study 10594527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/day conjugated equine oestrogens (CEE)
Number of subjects: 36
Study 10594527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/day conjugated equine oestrogens (CEE)
Number of subjects: 36
Study 10594527 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day conjugated equine oestrogens (CEE)
Number of subjects: 36
Study 10594527 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of CEE
Number of subjects: 36
Study 7773275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic testing in the coronal plane at 90 degrees/sec
Number of subjects: 20
Study 7773275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic testing in the scapular plane at 90 degrees/sec
Number of subjects: 20
Study 7773275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic testing in the coronal plane at 210 degrees/sec
Number of subjects: 20
Study 7773275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic testing in the scapular plane at 210 degrees/sec
Number of subjects: 20
Study 2085344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (CA), 1.3 g/day
Number of subjects: 569
Study 2085344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 569
Study 2085344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (CA)
Number of subjects: 569
Study 28278602 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-only treatment (ACTION Treatment; Stark et al., 2006)
Number of subjects: 40
Study 28666535 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare intervention alone (CC)
Number of subjects: 0
Study 28666535 — intervention group
Group type: EXPERIMENTAL
Intervention: Childcare intervention with parental involvement
Number of subjects: 0
Study 28666535 — intervention group
Group type: COMPARATOR
Intervention: Typical curriculum comparison group
Number of subjects: 0
Study 24691494 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 70
Study 24691494 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study 23674614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 T magnetic field exposure for 20 min
Number of subjects: 60
Study 23674614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to 3 T magnetic field)
Number of subjects: 60
Study 22030047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by misoprostol (100 μg or 50 μg)
Number of subjects: 40
Study 22030047 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (100 μg or 50 μg) alone
Number of subjects: 40
Study 19034052 — intervention group
Group type: EXPERIMENTAL
Intervention: E-EPA omega-3 fatty acid supplementation
Number of subjects: 120
Study 19034052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17453591 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interrupted therapy (SIT)
Number of subjects: 40
Study 17453591 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy (CT)
Number of subjects: 40
Study 15212115 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-induced cortical silent period (CSP) in SCA2 patients
Number of subjects: 20
Study 15212115 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-induced cortical silent period (CSP) in IDCA patients
Number of subjects: 20
Study 15212115 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 12377961 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma cell lysates (VMCL)
Number of subjects: 700
Study 12377961 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy (control)
Number of subjects: 700
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily conjugated equine estrogens
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus cyclical medroxyprogesterone acetate
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus daily medroxyprogesterone acetate
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus cyclical micronized progesterone
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-containing regimens
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate and micronized progesterone regimens
Number of subjects: 875
Study 9840563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 9840563 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, cognitive, and affective symptoms
Number of subjects: 875
Study 7856287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mumps vaccine, strain Sofia 6
Number of subjects: 0
Study 2570656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg twice daily
Number of subjects: 525
Study 2570656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 326281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg
Number of subjects: 28
Study 326281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg
Number of subjects: 28
Study 326281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 106
Study 30761665 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused treatment (PFT)
Number of subjects: 106
Study 28380223 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation by pre-service teachers
Number of subjects: 21
Study 28380223 — intervention group
Group type: COMPARATOR
Intervention: Evaluation by school mentors
Number of subjects: 21
Study 26394259 — intervention group
Group type: EXPERIMENTAL
Intervention: High whey yogurt (HW) C:W = 1.5:1
Number of subjects: 20
Study 26394259 — intervention group
Group type: EXPERIMENTAL
Intervention: +IN-βG yogurt (1.9 g of inulin and 0.5 g of β-glucan)
Number of subjects: 20
Study 26394259 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt (C:W = 2.8:1)
Number of subjects: 20
Study 26394259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-enriched formulations (2.4 g of inulin and 0.5 g of β-glucan)
Number of subjects: 20
Study 26394259 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with 0.5 g of β-glucan
Number of subjects: 20
Study 23480498 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Patient Pathway program (Internet-based patient educational program)
Number of subjects: 90
Study 23480498 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 90
Study 21241922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg, 3 times daily for 7 days (2 days before and 4 days after surgery)
Number of subjects: 83
Study 21241922 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 7 days (2 days before and 4 days after surgery)
Number of subjects: 83
Study 21241922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 83
Study 21241922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19225118 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:2 (safflower oil)
Number of subjects: 15
Study 19225118 — intervention group
Group type: EXPERIMENTAL
Intervention: 18:1 (canola oil)
Number of subjects: 15
Study 19225118 — intervention group
Group type: COMPARATOR
Intervention: Control (no fat infusion)
Number of subjects: 15
Study 16925697 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 104
Study 16925697 — intervention group
Group type: EXPERIMENTAL
Intervention: ocular blood flow pneumatonometer (OBFT)
Number of subjects: 104
Study 14682220 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic shock cardioversion (CV)
Number of subjects: 63
Study 14682220 — intervention group
Group type: COMPARATOR
Intervention: Biphasic shock cardioversion (CV)
Number of subjects: 63
Study 10857213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 2 mg daily in combination with ethinylestradiol (EE2) 35 mg or 50 mg
Number of subjects: 57
Study 10857213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 2 mg daily
Number of subjects: 57
Study 9088884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral SRI drugs (standardized treatment for 10 weeks)
Number of subjects: 30
Study 9088884 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned for the control group (absence of OCPD)
Number of subjects: 30
Study 8256902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg)
Number of subjects: 10